Community Advisory Board

Readers Rep

Markets:

Overview

News

Currencies

International

Treasuries

Ascendis Pharma A/S - Ordinary Share (NQ:ASND)

260.13 -0.68 (-0.26%)

Streaming Delayed Price Updated: 2:04 PM EDT, Sep 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ascendis Pharma A/S - Ordinary Share

< Previous 1 2 3 4 5 6 7 8 9 Next >

Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year ↗

September 16, 2024

Ascendis Pharma reports positive topline data from the Phase 3 ApproaCH trial of TransCon CNP in children with achondroplasia.

Via Benzinga

Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug ↗

September 16, 2024

The companies could soon face off in the growth treatment market for children with a genetic disorder.

Via Investor's Business Daily

Alcoa, Lattice Semiconductor, Stratasys And Other Big Stocks Moving Higher On Monday ↗

September 16, 2024

Via Benzinga

Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In ↗

September 04, 2024

Ascendis Pharma reported disappointing Q2 sales of $38.76 million, missing the consensus of $92.7 million. Key updates included a higher-than-expected U.S. price for Yorvipath and a delayed cash flow...

Via Benzinga

Why Ascendis Pharma Stock Tumbled by 11% Today ↗

September 04, 2024

A bottom-line whiff and reduced guidance made the company an outlier for the wrong reasons on Hump Day.

Via The Motley Fool

$100 Invested In This Stock 10 Years Ago Would Be Worth $5,900 Today ↗

August 09, 2024

Via Benzinga

$1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today ↗

July 18, 2024

Via Benzinga

Here's How Much $1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today ↗

July 03, 2024

Via Benzinga

Ascendis Pharma Slashes Its Outlook Amid Pricing Fiasco, Sacrifices A Breakout ↗

September 04, 2024

Shares are poised to undercut their 50-day and 200-day lines, and the lower boundary of a base.

Via Investor's Business Daily

Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut ↗

September 04, 2024

Ascendis Pharma reported lower-than-expected Q2 2024 sales of $38.76 million, missing the consensus estimate of $92.7 million due to a significant adjustment to prior sales estimates. The company...

Via Benzinga

Core & Main Reports Downbeat Results, Joins Rev Group, PagerDuty, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

September 04, 2024

Via Benzinga

Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement

September 03, 2024

Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes

From Royalty Pharma plc

Via GlobeNewswire

Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 15 Years ↗

June 26, 2024

Via Benzinga

If You Invested $100 In This Stock 15 Years Ago, You Would Have $4,100 Today ↗

May 31, 2024

Via Benzinga

(ASND) - Analyzing Ascendis Pharma's Short Interest ↗

May 28, 2024

Via Benzinga

Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday ↗

August 13, 2024

Via Benzinga

Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues ↗

August 12, 2024

FDA grants approval to Ascendis Pharma's Yorvipath (TransCon PTH) for adult hypoparathyroidism. Yorvipath offers continuous parathyroid hormone exposure and is set to launch in the U.S. with patient...

Via Benzinga

Ascendis Pharma Zips Higher After FDA Approves Embattled Thyroid Drug ↗

August 12, 2024

The company faced a number of regulatory setbacks that pushed its initial expected approval date out from April.

Via Investor's Business Daily

Macy's, Ascendis Pharma And 3 Stocks To Watch Heading Into Friday ↗

July 05, 2024

U.S. stock futures rise, Macy's receives higher offer, LGI Homes sells 571 homes, Telefonaktiebolaget records impairment charge, GFL declares dividend.

Via Benzinga

$100 Invested In This Stock 10 Years Ago Would Be Worth $6,500 Today ↗

May 17, 2024

Via Benzinga

$100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today ↗

May 06, 2024

Via Benzinga

ASND Stock Earnings: Ascendis Pharma Reported Results for Q1 2024 ↗

May 02, 2024

Ascendis Pharma just reported results for the first quarter of 2024.

Via InvestorPlace

FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months ↗

May 15, 2024

Ascendis Pharma announces FDA's extension of the review date for TransCon PTH for adults with hypoparathyroidism to August 14, 2024. TransCon PTH aims to address low calcium levels due to...

Via Benzinga

Masters In Trading - Saturday, May 11 ↗

May 11, 2024

In this recap of the most recent trading session, I discuss earnings results and the market rally seen throughout the past week.

Via Talk Markets

Looking Into Ascendis Pharma's Recent Short Interest ↗

April 26, 2024

Via Benzinga

$1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today ↗

April 18, 2024

Via Benzinga

Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion ↗

April 06, 2024

ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates...

Via Talk Markets

Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years ↗

April 03, 2024

Via Benzinga

Here's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today ↗

March 14, 2024

Via Benzinga

5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024 ↗

March 09, 2024

Things have been looking better for the biotech industry in 2024 after a decent performance in 2023. Here is a look at some biotech stocks that may provide stability to one's portfolio throughout the...

Via Talk Markets

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

About Us

Ascendis Pharma A/S - Ordinary Share (NQ:ASND)

All News about Ascendis Pharma A/S - Ordinary Share